Novavax reported 688.77M in Gross Profit on Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US 571K 1.21M
Agenus AGEN:US $ 18.9M 6.5M
AstraZeneca AZN:LN 728.3B 34.55B
Astrazeneca AZN:US 8.87B 244M
Biocryst Pharmaceuticals BCRX:US $ 65.28M 15.6M
Dynavax Technologies DVAX:US $ 173.1M 99.06M
GlaxoSmithKline GSK:LN 479.3B 29.3B
Mannkind MNKD:US $ 5.98M 4.99M
Merk MRK:US $ 10895M 328M
Moderna Inc MRNA:US 3.37B 1.68B
Novartis NVS:US $ 9336M 277M
Peregrine Pharmaceuticals PPHM:US $ 9.12M 2.13M
Pfizer PFE:US $ 19071M 3420M
Sarepta Therapeutics SRPT:US $ 195.69M 16.3M